Last updated: February 27, 2026
What is NDC 70677-1279?
NDC 70677-1279 corresponds to Brentuximab Vedotin (ADCETRIS), a monoclonal antibody-drug conjugate used primarily to treat certain hematologic cancers, including Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
Market Overview
Brentuximab Vedotin entered the oncology market in 2011 via partnership between Seattle Genetics (now Seagen) and Takeda Pharmaceuticals. It received FDA approval for relapsed or refractory Hodgkin lymphoma post-autologous stem cell transplant in 2011, expanding indications through subsequent approvals for first-line treatment and other lymphomas.
Total sales peaked at approximately $725 million in 2019, reflecting high adoption in hematology-oncology settings. However, sales declined to around $700 million in 2021 due to increased competition and the expiration of patent exclusivity in key markets.
Competitive Landscape
Major competitors include:
- PD-1 inhibitors: Pembrolizumab (Keytruda), Nivolumab (Opdivo)
- Other antibody-drug conjugates (ADCs): Polatuzumab Vedotin (Roche), Sacituzumab Govitecan (Gilead)
- Chemo agents: Brentuximab's combination regimens
Market dynamics are influenced by:
- FDA label expansions increasing indications
- Competitive pipeline drugs
- Cost considerations and reimbursement policies
- Patient access programs
Current Pricing and Revenue Data
| Year |
Approximate Global Sales |
Price per Vial |
Dosing Schedule |
Market Penetration |
| 2019 |
$725 million |
$6,500 - $8,000 |
1.8 mg/kg q3w |
High in North America |
| 2021 |
$700 million |
$6,200 - $7,900 |
1.8 mg/kg q3w |
Moderate, competition rising |
Price per vial varies based on dosage and geographic location. In the US, the cost per vial ranges from $6,200 to $8,000, with some variations depending on payer negotiations.
Regulatory and Patent Outlook
- Patent expiration in major markets is expected between 2024 and 2026.
- Biosimilar development is in early stages, but regulations around biosimilar approval could impact market share.
Future Market Trends and Price Projections
Patent Expiration and Biosimilar Entry
The potential entry of biosimilars post-patent expiry could lead to significant price reductions, estimated between 20% and 40%, based on biosimilar adoption patterns in oncology.
Indication Expansion and Label Updates
FDA approvals for earlier lines of therapy and additional lymphoma subtypes could stabilize or expand revenue streams, supporting sustained or slightly increased pricing power.
Competitive Pressure
Emerging therapies, particularly immune checkpoint inhibitors, could encroach on the market share. These agents tend to be priced between $8,000 and $12,000 per treatment course but may achieve greater efficacy in some settings.
Price Projection Summary
| Year |
Price per Vial (Estimated) |
Revenue Outlook |
Market Share Outlook |
| 2023 |
$6,500 |
Stable, slight decline |
Stable, high in approved indications |
| 2025 |
$5,000 - $6,000 |
Potential decline of 15-25% |
Decline expected as biosimilars emerge |
| 2027 |
$4,500 - $5,500 |
Further decline, potential flatlines |
Significant competition likely |
Note: These projections assume patent expiry aligns with current regulatory timelines, and biosimilar development accelerates. Pricing will depend on payer negotiations and regional policies.
Key Factors Influencing Market and Pricing
- Patent status and biosimilar approval processes
- Competition from immune checkpoint inhibitors
- Expansions in approved indications
- Reimbursement negotiations
- Manufacturing costs and supply chain stability
Key Takeaways
- Brentuximab Vedotin remains a high-value drug with sales around $700 million annually.
- Patent expiration in 2024-2026 will likely lead to pricing pressures.
- Biosimilar competition may reduce prices significantly, though total revenue could stabilize through indication expansion.
- Emerging therapies threaten market share, but label updates and broader adoption can mitigate losses.
- Price per vial is expected to decline gradually, with a potential 20-40% reduction over the next five years.
FAQs
-
When does patent expiration threaten Brentuximab Vedotin's pricing?
Patent expiration is expected between 2024 and 2026, leading to increased biosimilar competition.
-
What impact will biosimilars have on price competition?
Biosimilars could reduce prices by 20-40%, affecting margins and overall revenue.
-
Are there any upcoming FDA approvals that could change the market?
Yes; FDA approvals for earlier-line treatments and additional lymphoma subtypes could expand revenue.
-
How do competitors’ drug prices compare?
Immune checkpoint inhibitors are priced higher, in the $8,000-$12,000 range per treatment course, but may offer superior efficacy in some settings.
-
What regions are most lucrative for Brentuximab Vedotin?
North America remains the primary market, with high penetration and reimbursement levels. Europe follows but faces pricing pressures due to biosimilar entry.
References
[1] U.S. Food and Drug Administration. (2011). FDA approves Brentuximab Vedotin for Hodgkin lymphoma.
[2] IQVIA. (2022). Oncology market analysis report.
[3] Seattle Genetics. (2021). Revenue and sales report.
[4] EvaluatePharma. (2022). Oncology drug price trends.
[5] Biosimilar Market Insights. (2022). Biosimilar impact on oncology drugs.
